Liposuction in severe cases will be reimbursed in Germany

12

Mar 2020

In severe cases of lipedema, the costs for liposuction will be covered by the statutory health insurance companies from January 2020. The National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV) have added several new fee order items to the EBM (German Uniform Evaluation Standard) and set the reimbursement.

The liposuction, suction of the pathological fat tissue, aims to improve the mobility and thus alleviate the symptoms, often in several partial interventions. However, operative liposuction of lipedema in stage III can only be carried out if conservative therapy has not previously relieved the symptoms. This must have been carried out for at least six months and can include, for example, lymphatic drainage, compression, movement therapy.

The operation can then be performed and reimbursed on an outpatient basis or by a contracted doctor. The doctors will be billed up to 763€ per procedure. The costs for local anesthesia and the suction cannula used will be reimbursed additionally. Reimbursement will be procured via the following fee order items (GOPs), added to the EBM as of January 1, 2020:

  • 31096/36096 Liposuction for stage III lipedema (category AA6 intervention) with a tariff of 663,29€/419.93€
  • 31097/36097 Liposuction for stage III lipedema (category AA7 intervention) with a tariff of 708,01€/452.45€
  • 31098/36098 Surcharge for GOP 31096/36096 for simultaneous interventions and for GOP 31097/36097 with a tariff of 67.24€/41.42€
  • 31802/36802 Tumescent local anesthesia performed by the surgeon with a tariff of 284.79€/177.88€
  • 40165 The suction cannula (s) used during the procedure according to the GOP 31096 and 31097 with a tariff of 72.00€.

Doctors who want to perform liposuction for stage III lipedema require an outpatient surgery permit (in accordance with §135 paragraph 2 SGB V) and should be experienced in the treatment of lipedema.

The basis for liposuction reimbursement is the decision of the Federal Joint Committee (G-BA) of September 19, 2019. The inclusion of the method is initially limited to December 31, 2024, since the results of the trial initiated by the G-BA on liposuction in lipedema are expected to be ready by that date. As soon as the study results are available, the G-BA will finally decide on the method for all stages of the disease.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more